Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 25/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: Pacira BioSciences, Inc. is under scrutiny as a class action lawsuit has been filed against them for failing to disclose significant information during its Class Period. The lawsuit stems from a recent court ruling that invalidated a crucial patent for the company's main revenue generator, Exparel. Following this news, Pacira's shares plummeted by more than 47%. Investors have until March 14, 2025, to act if they suffered losses exceeding $100,000 during the relevant time frame.

Market Sentiment Analysis

CONCERNS & RISKS

  • Pacira is facing a class action lawsuit over failure to disclose material information.
  • The company experienced a significant share price drop of over 47% following a legal ruling.
  • Key patent for its major revenue product, Exparel, was deemed invalid.
  • Investors with over $100,000 in losses must act quickly to file claims.

Full Press Release Details

NEW ORLEANS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Pacira investors should visit us at https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything. On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file for lead plaintiff in Pacira's lawsuit?

Investors have until March 14, 2025, to file lead plaintiff applications.

Which securities are affected by the class action lawsuit?

The lawsuit involves Pacira securities purchased from August 2, 2023, to August 8, 2024.

What was the impact of the August 9, 2024 news on Pacira's shares?

Pacira's shares fell over 47% following the patent infringement ruling.

Where can investors find more information about their legal options?

Investors can visit https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call 844-367-9658.

Who is handling the Pacira securities class action?

The case is managed by Kahn Swick & Foti, LLC, attorneys for investors.

Last updated: Jan 23, 2025